Compounds and methods for treating cancer
AssigneeMayo Foundation for Medical Education and Research
InventorsJohn A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
Life of this patent
Estimating the term…
Abstract
This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.
Claims14
A method for treating a cancer in a human subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to Formula (II):
- or a pharmaceutically acceptable salt thereof,
- wherein
- R1 is halo,
- X is —(C═O)NR4—;
- Y is
- and
- R2, R3, and R4 are each independently H or an unsubstituted C1-6alkyl,
- wherein the cancer is selected from the group consisting of a kidney cancer, a liver cancer, a breast cancer, a lung cancer, a pancreatic cancer, a bladder cancer, a colon cancer, a melanoma, a thyroid cancer, an ovarian cancer, and a prostate cancer, and
- wherein the kidney cancer is clear cell renal cell carcinoma;
- and the bladder cancer is selected from the group consisting of:
- transitional cell carcinoma, urothelial carcinoma, papillary carcinoma, flat carcinoma, squamous cell carcinoma, adenocarcinoma, small-cell carcinoma, and sarcoma.
A method of treating a cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to Formula (II):
- or a pharmaceutically acceptable salt thereof,
- wherein
- R1 is halo;
- X is —(C═O)NR4—;
- Y is
- and
- R2, R3, and R4 are each independently H or an unsubstituted C1-6alkyl,
- and an mTor inhibitor, or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from the group consisting of:
- a kidney cancer, a liver cancer, a breast cancer, a lung cancer, a pancreatic cancer, a bladder cancer, a colon cancer, a melanoma, a thyroid cancer, an ovarian cancer, and a prostate cancer.
Dependencies are inferred from the claim text.